# PACIRA BIOSCIENCES, INC. (PCRX) FY2026 Q2 Balance Sheet

- Company: PACIRA BIOSCIENCES, INC. (PCRX)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-04, accession number 0001628280-26-052635
- Page: https://plicit.ai/financials/pcrx/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/pcrx-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 1,243,978,000 US dollars
- **Current assets**: 615,215,000 US dollars
- **Non-current assets**: 628,763,000 US dollars
- **Liabilities**: 572,002,000 US dollars
- **Current liabilities**: 122,011,000 US dollars
- **Non-current liabilities**: 449,991,000 US dollars
- **Equity**: 671,976,000 US dollars
- **Cash and cash equivalents**: 205,875,000 US dollars
- **Inventories, net**: 134,575,000 US dollars
- **Accounts receivable, net**: 132,420,000 US dollars
- **Assets held for sale**: 67,337,000 US dollars
- **Short-term available-for-sale investments**: 45,156,000 US dollars
- **Prepaid expenses and other current assets**: 29,852,000 US dollars
- **Intangible assets, net**: 285,484,000 US dollars
- **Fixed assets, net**: 130,277,000 US dollars
- **Deferred tax assets**: 124,598,000 US dollars
- **Right-of-use assets, net**: 44,920,000 US dollars
- **Investments and other assets**: 23,842,000 US dollars
- **Goodwill**: 19,642,000 US dollars
- **Accrued expenses**: 93,499,000 US dollars
- **Accounts payable**: 17,509,000 US dollars
- **Lease liabilities**: 10,298,000 US dollars
- **Liabilities held for sale**: 705,000 US dollars
- **Long-term debt, net**: 363,124,000 US dollars
- **Lease liabilities**: 38,695,000 US dollars
- **Other liabilities**: 26,650,000 US dollars
- **Contingent consideration**: 17,452,000 US dollars
- **Deferred tax liabilities**: 4,070,000 US dollars
- **Additional paid-in capital**: 1,087,452,000 US dollars
- **Accumulated other comprehensive income**: 3,241,000 US dollars
- **Common stock, par value $0.001; 250,000,000 shares authorized; 48,840,889 shares issued and 39,822,298 shares outstanding at June 30, 2026 and 47,890,777 shares issued and 41,116,739 shares outstanding at December 31, 2025**: 49,000 US dollars
- **Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at June 30, 2026 and December 31, 2025**: 0 US dollars
- **Treasury stock, at cost, inclusive of excise tax and broker fees, 9,018,591 and 6,774,038 shares at June 30, 2026 and December 31, 2025, respectively**: negative 227,013,000 US dollars
- **Accumulated deficit**: negative 191,753,000 US dollars
- **Gross equity (calculated)**: 1,090,742,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.